Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The designation "Other kinases with Kd <100 nM" is a categorical descriptor used in pharmacological profiling rather than a specific biological target. It refers to a subset of the kinome that demonstrates high binding affinity to a particular compound, characterized by a dissociation constant (Kd) of less than 100 nanomolar (Davis et al., 2011, Nature Biotechnology). In drug discovery, identifying these "other" kinases is crucial for evaluating the selectivity of kinase inhibitors and predicting potential off-target effects. Kinases as a class are essential enzymes that regulate nearly every cellular process by transferring phosphate groups to proteins, thereby altering their function (Manning et al., 2002, Science). When a drug candidate interacts with multiple kinases beyond its intended primary target, it can lead to unintended systemic consequences or unexpected therapeutic benefits. This classification helps researchers understand the broader impact of a molecule on the cellular signaling landscape and guides the optimization of chemical leads to improve safety and efficacy. High-affinity binding to off-target kinases is a common cause of toxicity in kinase inhibitor development (Karaman et al., 2008, Nature Biotechnology). Therefore, this grouping is a standard metric in kinome-wide competition binding assays to define the "selectivity hit" profile of a small molecule.
Inhibition of kinase catalytic activity via competitive or non-competitive binding at the ATP-binding site or allosteric sites.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Other kinases with Kd <100 nM.